WHO ICTRP trial
Relation between enzyme replacement therapy and progression of brain lesions in…
ISRCTN14072182 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN14072182 |
|---|---|
| Public title | Relation between enzyme replacement therapy and progression of brain lesions in Fabry disease |
| Scientific title | Magnetic resonance imaging of effect of enzyme replacement therapy on progression of cerebral white-matter lesions in Fabry disease: an observational study |
| Primary sponsor | University of Manchester |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | Not Applicable |
| Countries | United Kingdom |
| Conditions | Fabry disease Nutritional, Metabolic, Endocrine Fabry disease |
| Interventions | Retrospective analysis of a database and serial magnetic resonance imaging (MRI) scans to assess: 1. Progression of white matter lesions in patients with Fabry disease 2. Relation between disease progression and treatment with ERT |
| Registration date | Oct 2, 2015 |
| Target size | 100 |
| Secondary IDs | Nil known;NCT00196742;Nil known |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: